A052101
OPEN TO ACCRUAL
Ph 3 Study of Continuous v Intermittent Zanubrutinib Maintenance Therapy in Older Patients with MCL
ACCL1931
OPEN TO ACCRUAL
Ph3 Levocarnitine Prophylaxis for AYA in ALL Therapy
S2114
OPEN TO ACCRUAL
Ph II Trial of Consolidation Tx Following CD19 CAR T Tx for Relapse/Refractory DLBCL or Gr IIIB FL
UW19086
OPEN TO ACCRUAL
LTFU Protocol for Subjects Treated with Gene-Modified T Cells
UW20062
OPEN TO ACCRUAL
Metabolic Profiling of Leukemic Cells through Isotope Tracing in Patients with CLL
UW22057
OPEN TO ACCRUAL
Single Arm Ph I/II Study of Tazemetostat with Rituximab and Abbrev Bendamustine in Tx of HTBFL
UW22069
OPEN TO ACCRUAL
PH 2 Study MK-2140 in pts with Aggressive and Indolent B-Cell Malignancies
UW22157
OPEN TO ACCRUAL
Ph 1 Loncastuximab Tesirine Combo w DA-EPOCH-R in Pts w UnTx Aggress B-cell Lymphoid Malignancies
UW23106
OPEN TO ACCRUAL
Ph3 R open-label cmp efficacy of Glofitamab w POLA-R-CHP vs POLA-R-CHP in DLBCL
UW24107
OPEN TO ACCRUAL
Ph3 Study of Soquelitinib vs. Physician's Choice in Pts w/ R/R PTCL-NOS, FHTCL or sALCL